Strategic partnerships Leverage Strata Oncology’s model of partnering with major healthcare systems and a high-throughput CLIA lab to position as a collaborative solution provider for health systems seeking to integrate molecular profiling, decision support, and clinical trial access into standard care.

Precision medicine expansion Target biopharma and contracts with hospitals expanding precision oncology offerings; highlight Strata Select and multivariate biomarkers as differentiators to secure pilot programs and broader adoption across cancer centers.

Clinical trial access Emphasize access to matching therapies and drug trials as a driver for network expansion; align sales efforts with physicians seeking faster time to personalized treatment and trial enrollment within their patient populations.

Financial and growth signals Capitalize on recent $6.15M venture financing and ongoing high-growth trajectory to approach potential investors, system integrators, and hospital networks with scalable deployment models and ROI narratives.

Recognition and credibility Leverage industry awards and notable partnerships (e.g., Gilead collaboration) to build credibility when approaching large healthcare systems, demonstrating validated impact and external validation of Strata’s diagnostic and therapeutic matching capabilities.